Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins

(2018) Ronit Mazor et al.   AMERICAN JOURNAL OF PATHOLOGY

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

(2018) Robert J. Kreitman et al.   LEUKEMIA

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

(2018) Ronit Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1

(2018) Ronit Mazor et al.   CELLULAR IMMUNOLOGY

Hairy Cell Leukemia Treatment Approved

(2018)   Cancer Discovery

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors

(2018) Yasmin Leshem et al.   Toxins

Immunotoxins in cancer therapy: Review and update

(2017) Bahman Akbari et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma

(2017) Steve Y. Cho et al.   JOURNAL OF NUCLEAR MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

(2017) Yasmin Leshem et al.   Cancer Immunology Research

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Immunogenicity of therapeutic recombinant immunotoxins

(2016) Ronit Mazor et al.   IMMUNOLOGICAL REVIEWS

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

(2015) Y Andersson et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

New Life for Immunotoxin Cancer Therapy

(2015) R. Hassan et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood–brain barrier divide

(2013) Ann-Marie Chacko et al.   Expert Opinion on Drug Delivery

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Evolution of end points for cancer immunotherapy trials

(2012) A. Hoos   ANNALS OF ONCOLOGY

Host Translational Inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an Immune Response in Caenorhabditis elegans

(2012) Deborah L. McEwan et al.   Cell Host & Microbe

C. elegans Detects Pathogen-Induced Translational Inhibition to Activate Immune Signaling

(2012) Tiffany L. Dunbar et al.   Cell Host & Microbe

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Activation of Host Mitogen-Activated Protein Kinases by Secreted Legionella pneumophila Effectors That Inhibit Host Protein Translation

(2012) Mary F. Fontana et al.   INFECTION AND IMMUNITY

Secreted Bacterial Effectors That Inhibit Host Protein Synthesis Are Critical for Induction of the Innate Immune Response to Virulent Legionella pneumophila

(2011) Mary F. Fontana et al.   PLoS Pathogens

Inflammation 2010: New Adventures of an Old Flame

(2010) Ruslan Medzhitov   CELL

Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme

(2010) John K. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab

(2010) A. Ribas et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Shiga toxins — from cell biology to biomedical applications

(2009) Ludger Johannes et al.   NATURE REVIEWS MICROBIOLOGY

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

(2008) John H. Sampson et al.   NEURO-ONCOLOGY